Sanofi SA / Atomwise Inc.

AI-Driven Multi-Target Drug Discovery (Undisclosed Indications)

$1.5B AI drug discovery services market (2022) · ~85% Share of human proteome considered undruggable by traditional small molecules

Disease Overview

The Sanofi-Atomwise collaboration is a discovery-stage research deal indication-agnostic by design - up to five Sanofi-nominated targets across the company's pipeline focus areas (immunology and inflammation, oncology, diabetes/cardiovascular metabolism, vaccines, and rare diseases). The opportunity is best understood through the lens of the small-molecule discovery bottleneck: of the ~20,000 protein-coding genes in the human genome, only ~700 are currently drugged with small molecules, and ~85% of the proteome is considered undruggable by traditional methods. AtomNet - Atomwise's proprietary deep convolutional neural network for structure-based drug design - is designed to attack that gap by virtually screening libraries of >16 billion synthetically-tractable compounds against any protein structure to identify hit chemical matter at orders-of-magnitude lower cost and faster cycle time than physical high-throughput screening. The strategic indication relevance for Sanofi is that hit-identification across multiple TAs simultaneously is the dominant cost item in early R&D, and a single platform deal that supplies tractable hits against five novel targets has portfolio-level optionality that no single-disease deal could match.

Competitive Landscape

The AI drug discovery competitive landscape is highly fragmented with public, private, and big-pharma in-house entrants. Public AI-discovery peers: Recursion Pharmaceuticals (Phenom platform, Roche/Genentech $250M-$1.5B partnership 2021, Bayer fibrosis 2020), Schrodinger (physics-based + ML, BMS $270M-$2.7B 2020, Otsuka, Sanofi prior collaborations), Exscientia (Centaur Chemist, Bristol Myers Squibb $1.2B 2021, Sanofi $5.2B 2022 separate deal), Absci (deep learning antibody discovery, Merck collaboration 2022). Private peers: Insilico Medicine (Pharma.AI; ENPP1, USP1 programs licensed to Fosun and Exelixis), Insitro (ML+functional genomics, BMS $2B 2020, Gilead $1B 2019). Big-pharma in-house plays include Pfizer's CASP-X, AstraZeneca's iRED+BenevolentAI partnership, Novartis Microsoft Research alliance, GSK 23andMe genetics-driven targeting. The Sanofi-Atomwise deal sits in a portfolio with the larger Sanofi-Exscientia alliance ($5.2B biobucks announced January 2022) and Sanofi-BioMap (immunology AI 2022) - reflecting Sanofi management's clear preference for stacking multiple AI-discovery bets rather than picking a single platform winner.